MaxCyte, Inc.
MXCTNASDAQHealthcare● Active
$1.15
+$0.01(+0.88%)
Market Cap$123189923
P/E Ratio—
52W High$2.38
52W Low$0.643
MaxCyte, Inc. (MXCT) · Cash Flow
Annual, quarterly, or TTM views · SEC 10-K & 10-Q via FMP · adjust period and M/B/T below.
FMP · MXCT · as of 2026-06-10
Financial statements
Operating CF · CapEx · Free Cash Flow
| Breakdown | 2025-12 | 2024-12 | 2023-12 | 2022-12 | 2021-12 |
|---|---|---|---|---|---|
| Operating Activities | |||||
| Net Income | ($44.63M) | ($41.05M) | ($37.92M) | ($23.57M) | ($19.08M) |
| Depreciation & Amort. | $5.14M | $4.32M | $4.57M | $2.70M | $1.42M |
| Stock-Based Comp. | $9.21M | $0.00M | $13.98M | $0.00M | $7.96M |
| Change in Working Capital | ($6.12M) | ($0.75M) | $3.82M | ($3.21M) | ($1.64M) |
| Net Cash from Operations | ($34.41M) | ($27.61M) | ($21.69M) | ($14.78M) | ($10.68M) |
| Investing Activities | |||||
| Capital Expenditure | ($1.77M) | ($1.65M) | ($3.70M) | ($18.48M) | ($3.83M) |
| Purchases of Investments | ($126.29M) | ($150.86M) | ($255.09M) | ($290.94M) | ($268.68M) |
| Sales of Investments | $155.76M | $159.44M | $313.77M | $284.60M | $77.50M |
| Net Cash from Investing | $25.93M | $6.93M | $54.98M | ($24.82M) | ($195.01M) |
| Financing Activities | |||||
| Common Stock Repurchased | $0.00M | $0.00M | $0.00M | $0.00M | $0.00M |
| Dividends Paid | $0.00M | $0.00M | $0.00M | $0.00M | $0.00M |
| Debt Issued / Repaid | $0.00M | $0.00M | $0.00M | $0.00M | ($4.99M) |
| Net Cash from Financing | $0.66M | $2.06M | $2.14M | $2.89M | $234.72M |
| Free Cash Flow | |||||
| Free Cash Flow | ($36.18M) | ($29.26M) | ($25.39M) | ($33.26M) | ($14.51M) |
| FCF Margin %(computed) | -109.54% | -75.75% | -61.49% | -75.15% | -42.82% |
Data source: Financial Modeling Prep · Last updated: 2026-06-10 · USD · M
Explore more MaxCyte, Inc. data
About MaxCyte, Inc. (MXCT) Cash Flow Statement
MaxCyte, Inc. generated operating cash flow of ($0.03B) and free cash flow of ($0.04B) for 2025 — a FCF margin of -109.54%. Capital expenditure was ($0.00B).
Frequently asked questions
MXCT · 4 questionsMaxCyte, Inc. generated free cash flow of ($0.04B) for 2025, down 23.6% year-over-year.
MXCT free cash flowFCF margincash flow yield
· Source: FMP /stable/cash-flow-statement · SEC EDGAR Form 10-K & 10-Q · As of 2026-06-10